The relentless march of VEGF bispecifics
Two new pivotal Chinese first-line trials have started in lung cancer.
AstraZeneca goes early with Gracell
AZD0120’s first pivotal trial will test settings as early as the second line.
Pfizer mimics pumitamig in gastroesophageal cancers
The company will start a phase 2/3 trial of PF-08634404 in March.
Pivotal Claudin18.2 candidates keep coming
New pivotal trials will soon start for LaNova’s ADC and FutureGen’s MAb.
CSPC looks for HER2 white space
The company’s latest phase 3 for its biparatopic ADC is in colorectal cancer.
OnKure is no longer the only game in town
Cogent joins OnKure with a clinical-stage H1047Rm-specific PI3Kα inhibitor.
Astellas makes its KRAS degrader choice
The company discontinues one of its two KRAS G12D degraders.
Not so fast for AbbVie in SEZ6
A phase 3 trial is downgraded, and the second line now looks like the main focus for turmetabart adizutecan.
AbbVie scales back its GARP ambitions
After a phase 3 push the livmoniplimab plan falters.
